ZA200700205B - Antibodies for selective apoptosis of cells - Google Patents

Antibodies for selective apoptosis of cells

Info

Publication number
ZA200700205B
ZA200700205B ZA200700205A ZA200700205A ZA200700205B ZA 200700205 B ZA200700205 B ZA 200700205B ZA 200700205 A ZA200700205 A ZA 200700205A ZA 200700205 A ZA200700205 A ZA 200700205A ZA 200700205 B ZA200700205 B ZA 200700205B
Authority
ZA
South Africa
Prior art keywords
antibodies
cells
selective apoptosis
apoptosis
selective
Prior art date
Application number
ZA200700205A
Other languages
English (en)
Inventor
Reiter Yoram
Klechevsky Eynav
Denkberg Galit
Original Assignee
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Res & Dev Foundation filed Critical Technion Res & Dev Foundation
Publication of ZA200700205B publication Critical patent/ZA200700205B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200700205A 2004-06-09 2007-01-08 Antibodies for selective apoptosis of cells ZA200700205B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57792004P 2004-06-09 2004-06-09

Publications (1)

Publication Number Publication Date
ZA200700205B true ZA200700205B (en) 2009-09-30

Family

ID=35503572

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200700205A ZA200700205B (en) 2004-06-09 2007-01-08 Antibodies for selective apoptosis of cells

Country Status (7)

Country Link
US (1) US20100062001A1 (xx)
EP (1) EP1763365B1 (xx)
JP (1) JP2008501781A (xx)
AU (1) AU2005251563B2 (xx)
CA (1) CA2570458C (xx)
WO (1) WO2005120166A2 (xx)
ZA (1) ZA200700205B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102361971A (zh) * 2009-01-23 2012-02-22 Ns基因公司 改善的细胞系以及在胶囊化细胞生物递送中的用途
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
US9821073B2 (en) 2010-12-27 2017-11-21 Apo-T B.V. Polypeptide that binds aberrant cells and induces apoptosis
EP3613773A1 (en) * 2010-12-27 2020-02-26 Apo-T B.V. A cross linking polypeptide comprising an hexameric single chain antibody binding mhc-mage complex that induces apoptosis
EP2760892A1 (en) 2011-09-29 2014-08-06 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
US20130183307A1 (en) * 2012-01-13 2013-07-18 Johan Renes Aberrant cell-restricted immunoglobulins provided with a toxic moiety
BR112015003326A2 (pt) 2012-08-16 2017-07-04 Ipierian Inc métodos de tratamento de uma tauopatia
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US20160310583A1 (en) * 2013-10-03 2016-10-27 Sumitomo Dainippon Pharma Co., Ltd. Tumor antigen peptide
US10400018B2 (en) 2014-02-14 2019-09-03 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
CA3025894A1 (en) 2016-06-02 2017-12-07 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
CN113366019A (zh) * 2018-10-23 2021-09-07 科乐斯疗法公司 Alk2抗体及其使用方法
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837477A (en) * 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
JP2004503213A (ja) * 2000-03-27 2004-02-05 テクニオン　リサーチ　アンド　ディベロップメント　ファウンデーション　リミテッド １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法
CN1527954A (zh) * 2001-07-13 2004-09-08 NTT���ӹɷ����޹�˾ 光波导型矩阵开关及其制造方法
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
WO2003070752A2 (en) * 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
US20090226474A1 (en) * 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) * 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
EP1773383B1 (en) * 2004-05-27 2012-09-12 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
US20090042285A1 (en) * 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof

Also Published As

Publication number Publication date
WO2005120166A3 (en) 2006-08-10
AU2005251563A1 (en) 2005-12-22
WO2005120166A2 (en) 2005-12-22
JP2008501781A (ja) 2008-01-24
CA2570458A1 (en) 2005-12-22
AU2005251563B2 (en) 2011-08-04
CA2570458C (en) 2014-05-20
US20100062001A1 (en) 2010-03-11
EP1763365A2 (en) 2007-03-21
EP1763365B1 (en) 2016-08-10

Similar Documents

Publication Publication Date Title
ZA200700205B (en) Antibodies for selective apoptosis of cells
GB2441530B (en) Stem Cells
IL180852A0 (en) Anti-cd154 antibodies
IL181575A0 (en) Anti-ox40l antibodies
EP1781328A4 (en) METHOD FOR DETECTING SPECIFIC ANTIBODIES TO CANCER CELLS AND ANTIBODIES SOUND
IL234657A0 (en) Antibodies to p-cadherin
IL228033A0 (en) Antibodies
HRP20130440T1 (xx) Anti-p-selektin-protutijela
EP1807970A4 (en) TECHNIQUES FOR USING A RESERVE BANDWIDTH
IL179672A0 (en) Anti-cd3 antibodies
IL177602A0 (en) Uses of anti-ctla-4 antibodies
GB2411178A8 (en) Apparatus for culturing cells
EP1910688A4 (en) MULTICHANNEL FLOW CELLS
EP1869192A4 (en) FRAME MIXTURE OF ANTIBODIES
GB0420466D0 (en) Anti-glucan antibodies
HK1105993A1 (en) Anti-a33 antibody
EP1820852A4 (en) HUMAN SERUM FOR CELL CULTURE
ZA200703293B (en) Cell bandage
ZA200701952B (en) Anti-OX40L antibodies
EP1725652A4 (en) CULTURE PROCESSES OF CRYPTOSPORIDIUM
IL179956A0 (en) Antibodies for selective apoptosis of cells
GB0509318D0 (en) TCR-independent activation of T cells
GB0412861D0 (en) Screening of stem cells
IL178683A0 (en) Methods of diminishing co-abuse potenitial
PL373994A1 (pl) Sposób przygotowania komórek do badania apoptozy